ROBERT BACON: Open Payments
NPI 1700951704 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,112 in 73 payments from 14 companies in 2025. Trend: 2023 $911 · 2024 $1,387 · 2025 $2,112
Food & beverage: $2,112
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $538 |
| Teva Pharmaceuticals USA, Inc. | 10 | $377 |
| Neurocrine BioSciences, Inc. | 13 | $313 |
| Alkermes, Inc. | 8 | $289 |
| Otsuka America Pharmaceutical, Inc. | 8 | $179 |
| E.R. Squibb & Sons, L.L.C. | 7 | $170 |
| Bausch Health US, LLC | 3 | $68 |
| ABBVIE INC. | 3 | $62 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Lundbeck LLC | 1 | $22 |
Products named: CAPLYTA, INGREZZA, UZEDY, ARISTADA, COBENFY, AUSTEDO XR, LYBALVI, ABILIFY MAINTENA.
Industry payments across TX — which companies pay providers there.
